healthcare
healthcare Articles
Revolution Medicines entered the market with a bang on Thursday. Although the company only priced shares are $17 apiece, the stock actually entered the market closer to $28.
Published:
The January 31 short interest data have been compared with the previous figures, and short interest in most of these selected marijuana stocks increased.
Published:
CVS reported better than expected quarterly results before the markets opened on Wednesday, due in part to its acquisition of Aetna.
Published:
The January 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
The January 31 data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
CVS Health has faced strong headwinds since last year’s acquisition of health insurer Aetna, but its upcoming earnings report could prove to be a turning point.
Published:
The 2019–2020 flu season has already seen 22 million cases reported. The estimated impact on employers related to work absences is over $13 billion, according to Challenger, Gray & Christmas.
Published:
Amarin is a development-stage biotechnology company with one FDA-approved treatment, a cardiovascular disease drug with no real competition. The company looks well-poised to boost sales in 2020 and...
Published:
Collegium Pharma shares popped on Friday after the firm announced that it will acquire the U.S. rights to the Nucynta franchise from Assertio Therapeutics.
Published:
AbbVie released better than expected fourth-quarter financial results before the markets opened on Friday.
Published:
Aquestive Therapeutics shares jumped on Thursday after the firm announced that it had a constructive face-to-face meeting with the FDA concerning its “first of its kind” treatment of anaphylaxis.
Published:
Vivus shares jumped on Wednesday after the company announced a crucial FDA for its supplemental New Drug Application for an improved formulation of Pancreaze.
Published:
Merck reported fourth-quarter financial results before the markets opened on Wednesday that were essentially in line with expectations, yet shares retreated in early trading.
Published:
Merck is scheduled to release its fourth-quarter financial results before the markets open on Wednesday. Analysts are looking for year-over-year growth on the top and bottom lines.
Published:
Insmed is one of the few biotechs not tied to the coronavirus that is making a big move to start out the week. Essentially, the firm reported midstage study results for patients with non-cystic...
Published: